Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Forum Markets (NASDAQ:FRMM) Stock: Why Investors Are Reassessing the Tokenization Firm

Forum Markets, Incorporated (NASDAQ:FRMM) has become one of the more unusual small-cap stories on theNasdaqCapital Market this year, and its shares slipped again in early September 2026. The company began life pitching a blockchain platform for tokenizing real-world assets, but it has since pivoted …

Nitish Kishor | 10 September 2026

GlobeImmune's (OTC:GBIM) Yeast-Based Cancer Platform Belongs to an Earlier Immunotherapy Wave

GlobeImmune, Inc. (OTC:GBIM) is a name from an earlier wave of cancer-immunotherapy optimism that has long since faded from active coverage. The developer of the yeast-based Tarmogen platform once ran clinical programs in hepatitis B and oncology, but the stock now trades at the …

Nitish Kishor | 10 September 2026

Evelo Biosciences (OTC:EVLO) Stock: The Real Story Behind a Wound-Down Biotech

When a promising, Flagship Pioneering-founded biotech reaches a sub-penny quote, the percentage swings on any given day become almost meaningless. Evelo Biosciences, Inc. (OTC:EVLO) is a clear example.

Nitish Kishor | 10 September 2026

Merion's (OTC:EWLU) Supplement Business Spans Two Countries and Barely Registers a Trade

Few tickers embody the quiet limbo of the deep over-the-counter market like EWLU. Merion, Inc (OTC:EWLU), a small health and nutritional-supplements company with roots in both China and the United States, trades at a fraction of a cent and has barely registered a pulse …

Nitish Kishor | 10 September 2026

EyePoint (NASDAQ:EYPT) Stock: Digesting a Pivotal Trial That Missed Its Primary Goal

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) entered September 2026 nursing the aftermath of a pivotal clinical readout that fell short of Wall Street's hopes. The retinal-disease specialist has been under pressure since mid-August, when the first of two decisive late-stage trials for its lead eye drug …

Nitish Kishor | 10 September 2026

FibroBiologics (NASDAQ:FBLG) Stock: A Firm Session Ahead of First Clinical Data

A small Texas-based cell-therapy developer betting on fibroblasts, one of the body's most abundant cell types, FibroBiologics, Inc (NASDAQ:FBLG) has spent 2026 stacking up clinical and intellectual-property milestones that keep its name circulating among speculative biotech watchers. Trading onNasdaqunder the ticker FBLG, the stock …

Nitish Kishor | 10 September 2026

ENvue Medical (NASDAQ:FEED) Shares Drop: Why FEED Is Under Pressure

● Few tickers straddle the line between medical-device turnaround and speculative nano-cap as sharply as ENvue Medical.

Nitish Kishor | 10 September 2026

Eastgate Biotech (OTC:ETBI) Stock: What Investors Should Know About the Sub-Penny Biotech

Eastgate Biotech Corp. (OTC:ETBI) is a deeply speculative nano-cap whose story is defined more by illiquidity and scarce public disclosure than by any verifiable recent catalyst. Quoted on the OTC Pink market at fractions of a cent, the company's shares can register large percentage …

Nitish Kishor | 10 September 2026

EnviroTechnologies International (OTC:ETII) Is an Environmental Company Stuck on Health Screens

EnviroTechnologies International, Inc. (OTC:ETII) sits on watchlists under the ticker ETII, but the company is easily misfiled. Despite appearing in a health-and-technology screen, itsBusinessis environmental: non-toxic cleaning, sanitizing and anti-microbial products aimed at the oil-and-gas, food and agriculture sectors.

Nitish Kishor | 10 September 2026

Earth Science Tech (OTC:ETST) Stock: A Healthcare Roll-Up Adds Two More Acquisitions

Earth Science Tech has quietly reinvented itself from a former consumer-wellness name into an acquisitive healthcare roll-up, and 2026 has been its busiest stretch yet. The over-the-counter stock trades for pennies, so the small percentage move flagged at last closing means little on its …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…